Revascularization
In ISCHEMIA population, invasive group benefits from complete revascularization
Among patients with stable CAD assigned to an invasive strategy in the ISCHEMIA trial, those who achieved complete revascularization had better clinical and quality of life outcomes, researchers reported.
Rivaroxaban plus aspirin reduces total ischemic events in PAD after revascularization
Rivaroxaban plus low-dose aspirin reduced incidence of total severe CV and other adverse events in patients with peripheral artery disease who had lower-extremity revascularization, according to new data from the VOYAGER PAD trial.
FFR strategy may not top angiography strategy in STEMI, complete revascularization
Among patients with STEMI who underwent complete revascularization, a fractional flow reserve-guided strategy did not improve outcomes compared with an angiography-guided strategy, according to results of the FLOWER-MI trial.
Early discontinuation of DAPT after PCI increases long-term risk for adverse events
Long-term risk for coronary revascularization, MI and death persisted up to 5 years after premature discontinuation of dual antiplatelet therapy among patients who underwent PCI, researchers reported.
PDE5 inhibition may better improve survival, outcomes in stable CAD vs. alprostadil
In a comparison of two erectile dysfunction medications in men with stable CAD, phosphodiesterase type 5, or PDE5, inhibitors were associated with better survival and outcomes compared with alprostadil, researchers reported.
Evolocumab may reduce likelihood of future revascularization in established ASCVD
Evolocumab, a PCSK9 inhibitor, in addition to statin therapy for stable atherosclerotic CVD may lower risk for future revascularization with PCI or CABG, according to findings published in the Journal of the American College of Cardiology.
Drug-coated devices associated with less unplanned limb revascularization: VOYAGER PAD
Among patients with peripheral artery disease who had an endovascular procedure, treatment with a drug-coated device was linked to lower risk for unplanned limb revascularization, according to new data from the VOYAGER PAD trial.
DCB remains effective in real-world PAD population at 5 years
In a real-world population of patients with peripheral artery disease treated with a drug-coated balloon, nearly 70% remained free from clinically driven target lesion revascularization at 5 years, according to data presented at VIVA 20.
Procedural MI rates during revascularization vary widely based on definition
In two trials comparing outcomes of PCI with CABG, rates of procedural MI varied greatly depending on which definition was used, according to two analyses published in the Journal of the American College of Cardiology.
PET may be beneficial to guide revascularization strategy for CAD
PET perfusion and flow assessment may guide revascularization strategies for patients with CAD, according to a presentation at the Scientific Session and Exhibition of the American Society of Nuclear Cardiology.